The purpose of this memo is to provide an update to ADAP Management Memorandum 2021-02 (MM 2021-02) which announced the release of the Pre-Exposure Prophylaxis (PrEP) Assistance Program (PrEP-AP) generic PrEP policy. Generic tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was added to the PrEP-AP Formulary on January 4, 2021. At the time of the release of MM 2021-02, the only generic TDF/FTC was manufactured by Teva Pharmaceuticals, which established a generic PrEP savings card to be used towards the cost of the co-pays for insured individuals who qualified for their program. Previously, insured PrEP-AP clients, who were prescribed Teva's generic TDF/FTC and were in a health plan that did not cover the cost of PrEP, were required to use Teva's savings card towards the cost of the co-pay. The Teva Savings Card program expired March 29, 2021, and will not be renewed. Effective March 30, 2021, insured PrEP-AP clients are no longer required to use the Teva Savings Card if they are prescribed Teva's TDF/FTC and have a co-pay.

As of April 2021, additional pharmaceutical companies are manufacturing generic TDF/FTC. Most generic TDF/FTC medications are eligible for reimbursement by PrEP-AP. TDF/FTC labelers that are not eligible for reimbursement are notated on the PrEP-AP formulary.

PrEP-AP requests that you share this information with your clinical leadership team and local prescribers. You can reference the PrEP-AP Formulary for the most up to date information. Access to the updated formulary is available at the following URL: (https://cdphprep-ap.magellanrx.com/member/documents).

If you have any questions regarding the PrEP-AP generic PrEP policy, please contact PrEP-AP at PrEP.Support@cdph.ca.gov.

Thank you,